4D Molecular Therapeutics (FDMT) Cash & Equivalents (2019 - 2025)
Historic Cash & Equivalents for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $48.6 million.
- 4D Molecular Therapeutics' Cash & Equivalents fell 7410.94% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 7410.94%. This contributed to the annual value of $149.3 million for FY2024, which is 4005.17% down from last year.
- Per 4D Molecular Therapeutics' latest filing, its Cash & Equivalents stood at $48.6 million for Q3 2025, which was down 7410.94% from $77.2 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Cash & Equivalents registered a high of $275.7 million during Q3 2023, and its lowest value of $48.6 million during Q3 2025.
- Moreover, its 5-year median value for Cash & Equivalents was $149.3 million (2024), whereas its average is $157.8 million.
- Per our database at Business Quant, 4D Molecular Therapeutics' Cash & Equivalents surged by 37584.19% in 2023 and then crashed by 7410.94% in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Cash & Equivalents stood at $153.0 million in 2021, then plummeted by 65.78% to $52.4 million in 2022, then soared by 375.84% to $249.1 million in 2023, then plummeted by 40.05% to $149.3 million in 2024, then tumbled by 67.49% to $48.6 million in 2025.
- Its last three reported values are $48.6 million in Q3 2025, $77.2 million for Q2 2025, and $133.5 million during Q1 2025.